Molecular Targeting Technologies
Molecular Targeting Technologies is a privately held specialty life-sciences reagent company that develops and sells fluorescent probes, lipophilic dyes, radiopharmaceutical precursors, and imaging agents (CellVue®, NeuroVue®, PSVue®, SRfluor®, Duramycin products) to academic researchers and biotechnology companies through its mtarget.com e-commerce storefront and custom chemistry services.
- Company typePrivate
- Founded2012
- HeadquartersWest Chester, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Molecular Targeting Technologies does
Molecular Targeting Technologies, Inc. (MTTI) is a privately held specialty life-sciences reagent company founded around 2012 and headquartered in West Chester, Pennsylvania. The company develops, manufactures, and sells molecular imaging agents — fluorescent probes, radiopharmaceuticals, lipophilic dyes, and phosphatidylserine- and phosphatidylethanolamine-targeting compounds — to biomedical researchers. Its portfolio is organized around branded platforms: CellVue® (fluorescent cell membrane labeling kits, licensed-in technology), NeuroVue® (lipophilic far-red filter-based dyes for neural tract tracing, licensed from PTI Research), PSVue® (Zn-DPA–based anionic membrane probes), SRfluor® 680 (squaraine rotaxane dyes), and complementary lines including Lipophilic Cyanines, Immobilized Steroid Beads for affinity chromatography, Duramycin-based apoptosis probes with Kd of 4–6 nM, cyclic RGD and 2-DG optical imaging agents, and Glucarate-Kit/OsteoVue radiopharmaceutical precursors.
The company distributes most products directly through an e-commerce storefront at mtarget.com to academic laboratories, research institutions, and biotechnology and pharmaceutical companies, with unit pricing generally between $250 and $700 and quote-based pricing for custom chemistry services. Approximately 1–10 employees operate from a single West Chester office. MTTI holds exclusive license and sublicense rights to the NeuroVue® and CellVue® brands and several patents covering core chemistries. Leadership includes CEO Dr. Chris Pak (former Centocor/J&J radiopharmaceutical inventor, 20 prior IND filings) and CMO Dr. Danielle Meyrick (radiotheranostics executive with prior CMO roles at ITM Oncologic, Telix Pharmaceuticals, AdvanCell, and GenesisCare CRO). The firm has additionally launched the EvaThera sub-brand (EvaThera.com) to extend toward clinical-stage imaging agents and presented clinical data on the PRRT candidate EBTATE at SNMMI 2026, signaling a strategic move beyond catalog reagents.
Revenue is generated primarily through one-time catalog purchases of research reagents and contract-based custom synthesis services, with no disclosed institutional funding or revenue figures. MTTI has received regional recognition including 2019 Ernst & Young Entrepreneur of the Year finalist status (Greater Philadelphia) and a Ben Franklin Emerging Business Award.
Molecular Targeting Technologies firmographics
Firmographics- Name
- Molecular Targeting Technologies
- Legal name
- Molecular Targeting Technologies, Inc.
- Website
- https://mtarget.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Molecular Targeting Technologies is a privately held specialty life-sciences reagent company that develops and sells fluorescent probes, lipophilic dyes, radiopharmaceutical precursors, and imaging agents (CellVue®, NeuroVue®, PSVue®, SRfluor®, Duramycin products) to academic researchers and biotechnology companies through its mtarget.com e-commerce storefront and custom chemistry services.
- Ownership category
- akta.pro rank
Molecular Targeting Technologies industry classification
Industry- Product category
- Life Sciences Research Reagents
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industries
- Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD)
Keywords
Where Molecular Targeting Technologies is headquartered
LocationHeadquarters
- HQ city
- West Chester
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Molecular Targeting Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Research Products Sales: MTTI generates revenue through direct sales of fluorescent probes, imaging agents, cell membrane labels, and related biochemical products to research institutions, academic laboratories, and biotechnology companies. Products are sold through an e-commerce platform with pricing ranging from approximately $250 to $700 per unit depending on the product type and size.
- Custom Chemistry Services: The company offers custom synthesis and chemistry services for specialized research needs, including custom affinity absorbents for chromatography, ligand affinity binding studies, and protein-ligand complexes for crystallography.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard Research Products |
| Other | Multi-year contract | Custom Services |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Molecular Targeting Technologies product offering
Product offeringCore offering
Molecular Targeting Technologies (MTTI) develops, manufactures, and sells fluorescent labeling reagents, imaging agents, and affinity chromatography products for life sciences research. Its catalog spans branded product lines such as CellVue® (cell membrane labels), NeuroVue® (neural tract tracing dyes), PSVue® (phosphatidylserine-targeting probes), SRfluor® (squaraine rotaxane dyes), duramycin-based phosphatidylethanolamine probes, cyclic RGD peptides, radiopharmaceutical cold kits, and immobilized steroid beads, alongside custom chemistry services for specialized reagent synthesis.
Product overview
Molecular Targeting Technologies is a life sciences reagent company that develops and sells fluorescent labeling reagents, imaging agents, and affinity chromatography products for research applications. The product portfolio includes branded product lines: CellVue® (cell membrane labeling kits), NeuroVue® (neural tract tracing dyes), PSVue® (anionic membrane-targeting fluorescent probes), and SRfluor® 680 (squaraine rotaxane dyes), alongside complementary product families of Lipophilic Cyanines, Immobilized Steroid Beads, Duramycin-based apoptosis labels, Optical Imaging Agents (including cyclic RGD peptides and cancer-targeting agents), Click Chemistry Reagents, Crosslinkers, and Dyes for Bioconjugation. The company also offers Custom Chemistry Services for specialized synthesis. These products serve researchers in molecular imaging, cell biology, neuroscience, and drug discovery applications.
Differentiator
Problem solved
Functional benefit
Brands
- CellVue®: Fluorescent cell membrane labeling kits for tracking cell division and membrane staining
- NeuroVue®
- PSVue®
- SRfluor®
- EvaThera
Products and services
- CellVue® Fluorescent cell membrane labeling kits that stably label lipid regions of cell membranes; available in multiple spectral variants (Maroon, Claret, Plum, Burgundy, Lavender, Lilac, Red, Jade, NIR780, NIR815) for cell tracking and membrane staining research.
- NeuroVue® Lipophilic far-red emitting filter-based dyes for neural tract tracing studies; available in Maroon, Red, Orange, Burgundy, Jade, and Red Plus variants with tract tracing durations spanning 3 days to 3-4 weeks. Licensed from PTI Research, Inc.
- PSVue® Fluorescent probes with Zn-DPA targeting moiety that bind anionic membranes, including phosphatidylserine-targeting variants for apoptosis and microbial detection. Available in PSVue 380, 480, 550, 643, 794, Biotin, Control, and 499-WS (mSEEK) formulations.
- Lipophilic Cyanines DiI and DiO series of lipophilic carbocyanine dyes for cell membrane staining, available in various alkyl chain lengths (C2 to C28) with spectral properties spanning excitation/emission from 480/499nm to 748/780nm.
- Immobilized Steroid Beads Sepharose 4FF beads with immobilized steroid ligands (Estradiol, Nortestosterone, Dexamethasone, Androstan, Long Spacer Arm Dexamethasone, and custom options) for affinity chromatography, ligand binding studies, and protein-ligand complex crystallization.
- Duramycin Products Phosphatidylethanolamine (PE) binding agents including Duramycin and fluorescent conjugates (Cy3, Cy5, Cy7, Fluorescein, LC-Fluorescein, LC-Biotin, NODAGA). Duramycin binds PE with Kd of 4-6 nM at 1:1 ratio with exclusive specificity; NODAGA conjugate supports Ga-68 and Cu-64 radiolabeling for PET imaging.
- Optical Imaging Agents Fluorescence imaging agents including cyclic RGD peptides for integrin targeting (CyAL-5 cRGD, Cy3 cRGD, cRGD-LC-fluorescein), CyAL-5 2-Deoxyglucose for cancer targeting, and Tracer-653 for vascular imaging.
- SRfluor® 680 Lipophilic squaraine rotaxane far-red emitting dyes that accumulate at lipophilic sites inside living cells; available in Phenyl, azide, and Micellar Phenyl formulations for in vitro and in vivo applications.
- Click Chemistry Reagents Reagents for click chemistry reactions including crosslinkers used for bioconjugation and labeling applications.
- Crosslinkers Heterobifunctional linkers such as SANH (Succinimidyl 6-hydrazinonicotinate acetone hydrazone) used to introduce protected hydrazinonicotinimide functional groups into proteins, peptides, and surfaces.
- Dyes for Bioconjugation
Quantifiable outcome
- 99mTc-glucarate cold kit formulation for radiopharmaceutical preparation
- +1 more outcomes
Companies that use Molecular Targeting Technologies
Customer profileSegments3 records
Ideal customer profiles3 records
Molecular Targeting Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Molecular Targeting Technologies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- PTI Research, Inc.coreMTTI operates under license and sublicense agreements with PTI Research, Inc. for NeuroVue® and CellVue® products. These are core product lines for the company. The NeuroVue® brand is a trademark of PTI Research used under license, and CellVue® products are sold under sublicense from PTI Research, Inc.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Molecular Targeting Technologies competitors and assessment
Company assessmentDirect peers
- Click Chemistry Tools: Click Chemistry Tools sells heterobifunctional crosslinkers, click chemistry reagents, and bioconjugation dyes — directly overlapping with MTTI's Crosslinkers (SANH) and Dyes for Bioconjugation categories, and addressing the same research customer.
- LI-COR Biosciences: LI-COR is well known for IRDye infrared fluorescent dyes used in Western blots, microscopy, and in vivo imaging. Its IRDye platform competes directly with MTTI's NIR fluorescent probes (NIR780, NIR815) for near-infrared imaging research applications.
- Biotium: Biotium develops fluorescent probes and dyes for cell biology, neuroscience, and live-cell imaging — including membrane, nuclear, and organelle stains. The product overlap with CellVue®, PSVue®, and SRfluor® is tight, especially in fluorescent cell labeling kits sold via e-commerce.
- Vector Laboratories: Vector Laboratories develops labeling and detection reagents (immunohistochemistry, immunofluorescence, biotin-streptavidin systems) for research and clinical use. Its labeling reagent portfolio complements MTTI's Dyes for Bioconjugation and PSVue® Biotin products.
- ATTO-Tec GmbH: ATTO-Tec specializes in high-performance fluorescent labels (ATTO series) used in microscopy, flow cytometry, and single-molecule imaging. Their labeling chemistries and spectral breadth directly compete with MTTI's lipophilic cyanines and CellVue® spectral variants.
- AnaSpec / Eurogentec (Fujifilm): AnaSpec provides fluorescent peptides, custom peptide synthesis, and bioconjugation reagents — overlapping with MTTI's Custom Chemistry Services and Cyclic RGD Imaging Agents. Their custom synthesis offering is the most directly comparable service business.
- Cytodiagnostics: Cytodiagnostics manufactures lipid-based and gold nanoparticle imaging/labeling reagents including DiI/DiO analogs and custom surface functionalization. Its lipid membrane probe range directly competes with MTTI's Lipophilic Cyanines and PSVue® anionic membrane probes.
- Lumiprobe Corporation: Lumiprobe manufactures and sells a broad catalog of fluorescent dyes and labeling reagents for biomedical research, including cyanines, NHS esters, and specialty imaging probes. Its catalog scope and direct e-commerce model mirror MTTI's research products business most directly.
Broad incumbents
- Thermo Fisher Scientific (Molecular Probes / Invitrogen): Thermo Fisher's Molecular Probes / Invitrogen catalog is the gold-standard research fluorescent reagent brand, offering membrane stains, nuclear stains, and labeling kits across the same research applications MTTI targets. It represents the dominant competitive force in catalog research fluorescent reagents.
- PerkinElmer / Revvity: Revvity (formerly PerkinElmer Life Sciences) is a broad incumbent offering fluorescent imaging agents, radiopharmaceuticals, and preclinical imaging reagents through its Life Sciences portfolio. It competes with MTTI in optical imaging agents and radiopharmaceutical chemistry with much broader geographic reach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Molecular Targeting Technologies social profiles
Digital presenceMolecular Targeting Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molecular Targeting Technologies leadership team
Management profileNumber of profiles
Profiles2 records
Molecular Targeting Technologies funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molecular Targeting Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molecular Targeting Technologies
What does Molecular Targeting Technologies do?
Molecular Targeting Technologies (MTTI) develops, manufactures, and sells fluorescent labeling reagents, imaging agents, and affinity chromatography products for life sciences research. Its catalog spans branded product lines such as CellVue® (cell membrane labels), NeuroVue® (neural tract tracing dyes), PSVue® (phosphatidylserine-targeting probes), SRfluor® (squaraine rotaxane dyes), duramycin-based phosphatidylethanolamine probes, cyclic RGD peptides, radiopharmaceutical cold kits, and immobilized steroid beads, alongside custom chemistry services for specialized reagent synthesis.
Is Molecular Targeting Technologies a public or private company?
Molecular Targeting Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Molecular Targeting Technologies founded?
Molecular Targeting Technologies was founded in 2012. It employs 1 to 10 people.
Where is Molecular Targeting Technologies based?
Molecular Targeting Technologies is headquartered in West Chester, United States, in the North America region.
How does Molecular Targeting Technologies make money?
Two revenue lines are on record. Research Products Sales are the primary driver. The others are custom Chemistry Services.
Who are Molecular Targeting Technologies's main competitors?
Direct peers on record are Click Chemistry Tools, LI-COR Biosciences, Biotium, Vector Laboratories, ATTO-Tec GmbH, AnaSpec / Eurogentec (Fujifilm), Cytodiagnostics and Lumiprobe Corporation. Broad incumbents are Thermo Fisher Scientific (Molecular Probes / Invitrogen) and PerkinElmer / Revvity.
Does Molecular Targeting Technologies have an API?
No public API is recorded for Molecular Targeting Technologies.
What industry is Molecular Targeting Technologies in?
Molecular Targeting Technologies's product category is Life Sciences Research Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers). Its NAICS code is 325413 and its SIC code is 2835.